CA2769258A1 - Modified factor ix polypeptides and uses thereof - Google Patents

Modified factor ix polypeptides and uses thereof Download PDF

Info

Publication number
CA2769258A1
CA2769258A1 CA2769258A CA2769258A CA2769258A1 CA 2769258 A1 CA2769258 A1 CA 2769258A1 CA 2769258 A CA2769258 A CA 2769258A CA 2769258 A CA2769258 A CA 2769258A CA 2769258 A1 CA2769258 A1 CA 2769258A1
Authority
CA
Canada
Prior art keywords
fix
polypeptide
amino acid
poly
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2769258A
Other languages
English (en)
French (fr)
Inventor
Alan Brooks
Chandra Patel
Xiaoqiao Jiang
Uwe Gritzan
Heiner Apeler
Jun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2769258(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA2769258A1 publication Critical patent/CA2769258A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2769258A 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof Abandoned CA2769258A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
US61/230,551 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CA2769258A1 true CA2769258A1 (en) 2011-02-03

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2769258A Abandoned CA2769258A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Country Status (21)

Country Link
US (1) US20120164130A1 (en:Method)
EP (1) EP2461821A4 (en:Method)
JP (1) JP2013500726A (en:Method)
KR (1) KR20120060209A (en:Method)
CN (1) CN102573890A (en:Method)
AU (1) AU2010278721A1 (en:Method)
BR (1) BR112012002072A2 (en:Method)
CA (1) CA2769258A1 (en:Method)
CL (1) CL2012000238A1 (en:Method)
CR (1) CR20120052A (en:Method)
CU (3) CU20120018A7 (en:Method)
DO (1) DOP2012000030A (en:Method)
EA (1) EA201290069A1 (en:Method)
EC (1) ECSP12011637A (en:Method)
GT (1) GT201200023A (en:Method)
IN (1) IN2012DN00908A (en:Method)
MX (1) MX2012001346A (en:Method)
PE (1) PE20121643A1 (en:Method)
SG (1) SG178119A1 (en:Method)
WO (1) WO2011014890A1 (en:Method)
ZA (1) ZA201200716B (en:Method)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
TR201813067T4 (tr) 2008-09-15 2018-09-21 Uniqure Biopharma B V Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem.
WO2011017055A2 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2806684C (en) * 2010-07-30 2020-11-17 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP6138052B2 (ja) 2010-12-22 2017-05-31 バクスアルタ ゲーエムベーハー 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法
BR112014014454B1 (pt) * 2011-12-19 2021-03-09 Dilafor Ab glicosaminoglicanos não anti-coagulativos compreendendo unidade de dissacarìdo repetida e seus usos médicos
EP2922871B1 (en) * 2012-11-20 2019-06-19 The University of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
BR112015021364A2 (pt) * 2013-03-13 2017-10-10 Ambrx Inc polipeptídeos de leptina canina modificados
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
WO2018022844A2 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
BR112021007301A2 (pt) 2018-10-18 2021-07-27 Intellia Therapeutics, Inc. composições e métodos para expressar fator ix

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
BRPI0417341A (pt) * 2003-12-03 2007-04-17 Neose Technologies Inc fator ix glicopeguilado
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP2423306A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
EP2461821A1 (en) 2012-06-13
EA201290069A1 (ru) 2012-07-30
CU20120018A7 (es) 2012-06-21
SG178119A1 (en) 2012-03-29
IN2012DN00908A (en:Method) 2015-04-03
CU20130058A7 (es) 2013-06-28
ZA201200716B (en) 2013-07-31
CN102573890A (zh) 2012-07-11
WO2011014890A1 (en) 2011-02-03
GT201200023A (es) 2014-01-27
AU2010278721A1 (en) 2012-02-16
PE20121643A1 (es) 2012-11-25
DOP2012000030A (es) 2012-02-29
ECSP12011637A (es) 2012-02-29
JP2013500726A (ja) 2013-01-10
US20120164130A1 (en) 2012-06-28
CL2012000238A1 (es) 2012-10-05
BR112012002072A2 (pt) 2016-11-08
EP2461821A4 (en) 2013-07-03
KR20120060209A (ko) 2012-06-11
CR20120052A (es) 2012-06-04
MX2012001346A (es) 2012-02-17
CU20130057A7 (es) 2013-06-28

Similar Documents

Publication Publication Date Title
US20120164130A1 (en) Modified Factor IX Polypeptides and Uses Thereof
KR20110015551A (ko) 제ｉｘ인자의 부위-지정 변형
US20090252720A1 (en) Prolonged FIX Analogues and Derivatives
JP5876208B2 (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
KR101146160B1 (ko) 중합체­인자 ｉｘ 부분의 접합체
KR102068133B1 (ko) 혈액 응고 단백질 복합체
US20080227691A1 (en) Blood Coagulation FVIII Analogues
CN102083856A (zh) 经修饰的因子ix多肽及其用途
HK1172840A (en) Modified factor ix polypeptides and uses thereof
HK1153383A (zh) 因子ix的定點修飾
HK1153481A (en) Modified factor ix polypeptides and uses thereof
AU2012203323A1 (en) Polymer-factor IX moiety conjugates

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160803